Statins, Mortality, and Major Adverse Cardiovascular Events Among US Veterans With Chronic Kidney Disease

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among older adults with chronic kidney disease (CKD).1 Yet, data for the role of statins for primary ASCVD prevention in individuals with moderate CKD (stages 3-4) are limited. A meta-analysis of 8834 participants in primary prevention trials with CKD, primarily stage 3, reported a 41% reduction in ASCVD events and a 34% reduction in total mortality.2 Conversely, there is evidence that there is no benefit to initiating statins in persons receiving hemodialysis.3-5

This publication has 44 references indexed in Scilit: